NAD+ injectable

What it is

Nicotinamide adenine dinucleotide, usually abbreviated NAD+ in its oxidized form, is a small molecule found in living cells rather than a peptide. It is central to cellular metabolism because the NAD+/NADH redox pair transfers electrons in biochemical reactions involved in fuel oxidation and mitochondrial energy production^{[1 –2 ]}. NAD+ also acts as a consumed substrate for signaling and repair enzymes, including sirtuins, poly(ADP-ribose) polymerases, and CD38-family enzymes^{[1 –2 ]}.

The scientific history of NAD+ is older than the modern peptide-therapy market. Early 20th-century yeast-fermentation research identified a heat-stable factor required for fermentation, later understood as part of the coenzyme chemistry now associated with NAD+ and NADH^{[1 –2 ]}. Modern interest in NAD+ increased after research connected NAD+ metabolism with aging biology, mitochondrial function, inflammation, DNA repair, and metabolic disease models^{[1 ]}.

NAD+ biology should not be confused with evidence for NAD+ injections. The fact that NAD+ is essential inside cells does not by itself establish that externally infused NAD+ reaches target tissues, raises intracellular NAD+ in clinically meaningful ways, or improves disease outcomes^{[1 ,3 ]}. This distinction matters because many public claims about NAD+ IV therapy extrapolate from basic NAD+ biology or from studies of oral NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide, which are different interventions^{[1 ]}.

When used in clinical or wellness settings, injectable NAD+ is typically described as an intravenous infusion and, less commonly, as intramuscular or subcutaneous injection. Published human research includes a 6-hour intravenous infusion metabolomics study and a randomized trial using intravenous NAD+ in hospitalized patients with heart failure due to ischemic cardiomyopathy^{[3 –4 ]}. These administration descriptions are not dosing guidance and do not imply that NAD+ injection is appropriate for any condition.

Regulatory status

NAD+ injectable products are not FDA-approved prescription drugs for any specific indication identified in this review. FDA warning letters have treated marketed or repackaged NAD+ injectable products as unapproved new drugs when no approved application was in effect, including a February 2026 warning letter referring to NAD+ 50 mg/mL injection products^{[10 ]}. FDA has also warned compounders about the use of food-grade NAD+ in sterile intravenous products because of microbial and endotoxin contamination risks^{[11 ]}.

503A bulks-list status

For 503A pharmacy compounding, NAD occupies a specific interim category. FDA’s April 22, 2026 list of bulk drug substances nominated for use under section 503A includes “Nicotinamide Adenine Dinucleotide (NAD)” in Category 1, meaning it is under evaluation^{[6 ]}. FDA’s 503A guidance page states that Category 1 substances may remain within an interim enforcement-discretion policy if the conditions in the guidance are met^{[5 ]}. This is not the same as FDA approval, and it is not a final determination that NAD belongs on the formal 503A bulks list^{[5 –6 ]}.

Ingredient identity matters. The same April 2026 FDA 503A document lists “Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate” separately in Category 3, which is for substances nominated without adequate support^{[6 ]}. That distinction should be reviewed by counsel and pharmacy compliance specialists before any provider or platform is listed as offering a compliant NAD+ injectable product.

503B outsourcing-facility status

For 503B outsourcing facilities, the status is more restrictive. FDA’s 503B page states that outsourcing facilities may use a bulk drug substance only if the substance appears on the 503B bulks list or the compounded drug appears on FDA’s drug shortage list at the time of compounding, distribution, and dispensing^{[7 –8 ]}. NAD+ does not appear among substances included on the 503B bulks list as of the FDA page reviewed for this draft^{[7 ]}. In a January 2026 warning letter to GenoGenix, FDA stated that drug products compounded using NAD+ were not eligible for 503B exemptions because NAD+ did not appear on the 503B bulks list and was not used to compound a drug on the shortage list^{[9 ]}.

Controlled-substance and recent FDA actions

NAD+ is not listed in the federal controlled-substance schedules in 21 CFR Part 1308^{[12 ]}. This does not make NAD+ injection FDA-approved or establish that any particular compounded product is lawful. DEA scheduling and FDA approval are separate legal questions.

Notable recent FDA actions include a sterile-compounding alert about food-grade NAD+ being used to make IV products, reports of severe chills, shaking, vomiting, and fatigue after NAD+ injectable drugs, and warning-letter findings involving excessive endotoxins in an NAD+ compounded product^{[9 ,11 ]}. Date of last regulatory update verification: May 6, 2026.

Research summary

The evidence base for injectable NAD+ is much smaller than the evidence base for NAD+ biology or oral NAD+ precursors. NAD+ is clearly important in cellular metabolism, redox reactions, DNA repair signaling, and enzyme systems implicated in aging biology^{[1 –2 ]}. However, most therapeutic research on “boosting NAD+” has studied precursors such as NR, NMN, niacinamide, or pathway modulation, not direct NAD+ infusion^{[1 ]}. These categories should not be treated as interchangeable.

Pilot pharmacokinetics: Grant 2019

A small human pharmacokinetic and metabolomics study by Grant and colleagues investigated plasma and urine NAD+ metabolites during a 6-hour IV NAD+ infusion^{[3 ]}. The study enrolled 11 male participants, with 8 receiving NAD+ and 3 controls^{[3 ]}. At the infusion rate studied, plasma NAD+ and measured metabolites did not rise during the first 2 hours; later changes suggested rapid metabolism involving NAD+ glycohydrolase and pyrophosphatase activity, with urinary excretion of NAD+ and methyl nicotinamide^{[3 ]}. This was not an efficacy trial and did not test whether NAD+ infusion improves fatigue, cognition, addiction outcomes, athletic recovery, or longevity.

Ischemic cardiomyopathy heart-failure RCT: Yu 2026

The main clinical outcomes trial identified for injectable NAD+ is a single-center randomized, placebo-controlled trial in adults with heart failure caused by ischemic cardiomyopathy^{[4 ]}. Yu and colleagues enrolled 180 adults with left ventricular ejection fraction of 45% or lower and NYHA class II–III symptoms; participants received intravenous NAD+ or placebo for 7 days in addition to guideline-directed medical therapy^{[4 ]}. At 1 month, the NAD+ group had a higher mean LVEF than the placebo group, 45.44% versus 42.44%, with a reported p value of 0.024^{[4 ]}. Secondary endpoints including NT-proBNP, major adverse cardiac and cerebrovascular events, heart-failure hospitalization, and NYHA improvement were reported as favorable trends but were not statistically significant in the abstracted results^{[4 ]}.

That heart-failure trial is clinically interesting but narrow. It studied a specific hospitalized cardiovascular population, used short-course IV administration, and was conducted at a single center^{[4 ]}. It does not establish benefits for wellness uses such as “energy,” “anti-aging,” “detox,” hangover recovery, post-travel fatigue, athletic performance, or substance-use recovery. Those claims are common in public-facing NAD+ marketing, but this review did not identify large randomized clinical trials supporting them as of May 6, 2026.

Where the evidence ends

Preclinical literature supports the broader concept that NAD+ metabolism can influence cardiometabolic, inflammatory, renal, neurological, and aging-related pathways^{[1 ]}. But many animal studies use NAD+ precursors or genetic/pharmacologic manipulation of NAD+-consuming enzymes rather than direct IV NAD+^{[1 ]}. Translation from those models to injectable NAD+ in humans remains uncertain.

Overall, the quality of evidence for injectable NAD+ is preliminary. There is one small human IV metabolomics study, one randomized single-center heart-failure trial, and extensive mechanistic rationale from NAD+ biology^{[1 –4 ]}. There are no large multicenter randomized trials establishing injectable NAD+ as a treatment for aging, cognitive decline, addiction, fatigue, athletic recovery, or general wellness as of this review date.

Public discourse

Andrew Huberman, PhD, neuroscientist and host of the Huberman Lab podcast, discussed personal experience with NAD+ infusions on a 2023 AMA episode, reported subjective post-infusion improvement, emphasized discomfort during the infusion, and acknowledged the lack of clinical-trial evidence for vigor-related claims^{[13 –14 ]}.

Eric Verdin, MD, geroscientist and CEO of the Buck Institute for Research on Aging, discussed NAD+ biology, sirtuins, CD38, NR and NMN, and expressed skepticism about IV NAD+ because NAD+ is primarily intracellular and may be metabolized before producing the intended cellular effect^{[15 –16 ]}.

Peter Attia, MD, longevity-focused physician and host of The Peter Attia Drive, framed the NAD+ and sirtuin field as scientifically interesting but complicated by commercialization and insufficiently rigorous human testing. The discussion focused more on NAD+ precursors and aging biology than on injectable NAD+ as a medical treatment^{[15 –16 ]}.

Rhonda Patrick, PhD, biomedical scientist and founder of FoundMyFitness, discussed NAD+ biology and NAD+ precursor strategies on the Joe Rogan Experience and expressed caution about direct NAD+ IV therapy because clinical evidence and cellular delivery were unresolved^{[17 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Because injectable NAD+ has not gone through FDA drug approval, there is no FDA-approved prescribing information that systematically defines indications, dosing, contraindications, drug interactions, or adverse-reaction rates for an approved NAD+ injectable product. Published human safety data are limited to small or indication-specific studies rather than large safety databases^{[3 –4 ]}.

In the Grant metabolomics pilot study, the design was too small to characterize uncommon adverse events or long-term safety^{[3 ]}. In the Yu heart-failure trial, participants were treated in a specific cardiovascular context and followed for cardiac outcomes; those data should not be generalized to outpatient wellness infusions^{[4 ]}.

Sterility, endotoxin, and product-quality concerns

FDA has identified practical safety concerns around sterile injectable NAD+ products. The agency reported awareness of compounders using food-grade NAD+ to make intravenous products and warned that food-grade ingredients are not suitable for sterile compounding without appropriate processing because of risks from microbes and endotoxins^{[11 ]}. FDA also reported adverse events after NAD+ injectable drugs, including severe chills, shaking, vomiting, and fatigue, with some cases requiring medical treatment^{[11 ]}.

A January 2026 FDA warning letter described a complaint investigation in which three patients developed low blood pressure, uncontrollable shaking, shivers, and body aches shortly after or during administration of an NAD+ product from the same vial; an unopened vial from the same lot reportedly contained excessive bacterial endotoxins^{[9 ]}. This episode is a product-quality and sterility issue, not proof that pharmaceutical-grade NAD+ itself necessarily causes those reactions, but it illustrates the special risk profile of injectable compounded products.

Other clinical concerns

Theoretical and practical concerns include infusion reactions, nausea, chest or abdominal discomfort during infusion, hypersensitivity, complications from IV access, contamination, endotoxin exposure, and unknown effects in people with active malignancy, pregnancy, severe renal or hepatic disease, or complex cardiometabolic illness. Drug-interaction data for injectable NAD+ are not well established in clinical research. Long-term safety data for repeated outpatient NAD+ injections or infusions are limited.

Available through

No telehealth platform or clinic network is listed for NAD+ injectable as of 2026-05-06.

NAD+ injectable products are not FDA-approved drug products. Patient-specific 503A compounding may fall within FDA’s interim policy only if the relevant legal and quality conditions are met, while FDA has stated that NAD+ is not eligible for 503B outsourcing-facility exemptions when it is not on the 503B bulks list and is not used to compound a shortage-list drug^{[5 –11 ]}.

ProPeptideGuide does not link to or endorse grey-market vendors, research-chemical suppliers, food-grade injectable ingredients, or NAD+ products marketed with unapproved disease-treatment claims. No provider will be added until legal review confirms that the offering is patient-specific, 503A-compliant where applicable, uses suitable sterile-compounding ingredients, and does not rely on prohibited 503B outsourcing-facility compounding or repackaging.